Health-related content. Aggregated from public sources for informational purposes only. This is not medical advice. Consult a qualified professional before making decisions. .

Embraya: IVF Tracker

Embraya: IVF Tracker

By Embraya

Embraya is an IVF medication tracker and cycle planning app for iOS and Android that allows users to manage multiple treatment cycles and medical history.

The App DNA

What makes this app unique?

Users hire Embraya to offload the high mental burden of managing complex, time-sensitive IVF medication schedules and appointments, replacing manual spreadsheets with a structured digital record.

For Individuals undergoing IVF treatment who need a centralized, organized way to manage complex medication schedules, appointments, and medical history.

What does it look like?

Key features

Multi-Cycle Managementedge

Tracks multiple IVF treatment cycles, allowing users to switch between retrievals and transfers while maintaining historical data.

Guided Medication Schedulingedge

Provides reminders, inventory tracking, and injection side rotation for IVF medications.

Embryo Bankedge

Logs embryo grades, PGT-A/PGT-M results, transfer dates, and storage status.

How much does it cost?

freemiumFree access to core featuresPaywall-gated advanced functionality

The app has transitioned from a free tool to a paywall-gated model, which has triggered negative sentiment among early users.

Velocity

Maintenance developmentnew contentUX improvementsShow more...

Embraya: IVF Tracker shows a maintenance-level release cadence based on the provided history. The latest version is a significant update that adds comprehensive tracking features for medical data, expenses, and personal wellness. Development is currently focused on expanding core utility rather than frequent iterative updates. Future momentum will depend on whether this feature-rich release is followed by regular maintenance or further expansion.

See all version history

Who built it?

Embraya

2 apps tracked · Health & Fitness

Embraya: IVF Cycle TrackerEmbraya: IVF Cycle Tracker
Explore the full publisher profile

User Sentiment

What do users think recently?

Recent user voice shows a frustrated sentiment. Users appreciate the comprehensive tracking features effectively reduce the mental load for users managing their fertility journey.

How are ratings & reviews evolving?

App Store
5.00 · 21
Google Play
0.00 · 0

What users say, by theme

What Users Love
  • The comprehensive tracking features effectively reduce the mental load for users managing their fertility journey
What Frustrates Users
  • Medication notification timing shifts post-update prevent users from adhering to strict fertility treatment schedules
+ 1 more theme

3 of 3 recent reviews analyzed · limited sample

Read the full review analysis

Unlock 1 more frustration theme, each backed by review evidence.

Access the full report for free

Competition

Competitive landscape for Embraya: IVF Tracker

How's the Health & Fitness market?

Embraya operates in the Health & Fitness category, currently holding a 5-star rating across 21 reviews on iOS. The lack of Android reviews suggests a nascent presence on the platform, signaling that the app is currently in an early-stage acquisition phase.

Read the market outlook

The rivals identified

Unlock the deeper market read.

Access the full report for free

The Analyst's Read

Key takeaways for Embraya: IVF Tracker

Where is it heading?

The fertility tracking market is increasingly sensitive to reliability, as users rely on these tools for time-critical medical protocols. Embraya's recent technical regressions and monetization shifts suggest a pivot toward revenue that currently outpaces its product stability, so the PM must stabilize the core notification loop to prevent churn.

  • Notification latency in the latest version creates adherence risks, which erodes the core utility of the app for IVF patients.
  • The introduction of a paywall has triggered immediate user frustration, signaling potential friction in the current acquisition funnel.

The SWOT

Core Strengths
  • Multi-cycle historical tracking creates a longitudinal medical record
  • Phase-based educational content reduces upfront cognitive load
Critical Frictions 2 weaknesses inside
Growth Levers
  • Integration with fertility clinic portals could automate data entry
Market Threats 1 threat identified

Next best moves

1 Pivot · 1 Invest

Rebuild notification service because late alerts cause medication adherence failures → restore user trust

+ 1 more prioritized move

The counter-intuitive read

The move to a paywall is premature…

Read the full take

Since the last report: The app transitioned to a freemium pricing model, which has introduced user friction and shifted the competitive outlook to mixed.

Bottom line

Embraya provides unique value through its multi-cycle tracking mechanism, but technical instability in medication reminders and an aggressive paywall threaten its adoption, so the PM must prioritize notification reliability before expanding monetization gates.

Unlock 2 critical frictions, 1 market threat, 1 more prioritized move and the analyst’s take.

Access the full report for free

Sources

  1. [1] App Store, source

Report last updated

Disclosure: Independent intel to help mobile builders succeed.

AI-powered analysis with automated quality gates, built from publicly available sources. Marlvel.ai is not affiliated with, endorsed by, or sponsored by Embraya: IVF Tracker, its developer, the app publisher, Apple, or Google Play. All trademarks, logos, and screenshots referenced remain the property of their respective owners.

What's new

The app transitioned to a freemium pricing model, which has introduced user friction and shifted the competitive outlook to mixed.

shifted

Transition to Freemium Model

shifted

Outlook Trend Adjustment

added

New SWOT Insights

Cite this report

Marlvel.ai. “Embraya: IVF Tracker Intelligence Report.” Updated Aug 8, 2026. https://marlvel.ai/apps/embraya-ivf-tracker

Agent Markdown (.md)See methodologyContact support

Data licensed under CC-BY-NC 4.0